Thomas Dann is President and Co-Founder of MedLiquidity Corporation, a novel data analytics platform enabling the real-time securitization of healthcare claims. He is also Managing Director of Castlehaven Advisors, LLC, advising venture funds and technology companies.  He was formerly Vice President of Cellphire Therapeutics, Inc., a groundbreaking biotech company developing a platelet substitute with broad applications in trauma, anti-coagulant reversal, and intracranial hemorrhage.   Mr. Dann is an experienced venture investor, formerly Managing Director of the Maryland Venture Fund, the $120M early-stage venture program funded by Maryland which has invested into private venture funds as well as scores of start-ups and early-stage companies across a wide range of industry sectors. Dann's professional career has been focused on venture investing, private equity, and public and private initiatives to foster entrepreneurship and job creation. Dann previously founded ECentury Capital Partners, a $90 million early-stage venture fund where he served as managing director and general counsel, and he was a Venture Partner and Director of GIV Venture Partners.  Mr. Dann holds a B.A. from Stanford University and a JD from the American University Law School. He is a member of the Maryland Bar.

Azra Raza is the Chan Soon-Shiong Professor of Medicine and Clinical Director of the Edward P. Evans Foundation MDS Center at Columbia University in New York. A practicing oncologist seeing 30-40 cancer patients weekly, she directs a basic cancer research lab with hundreds of original publications in high profile journals. Her life is dedicated to prevention of all chronic diseases including cancer by early detection. She worked with President Clinton designing Breakthrough Developments in Science and Technology and with President Joe Biden for the Cancer Moonshot initiative. Her latest book, THE FIRST CELL: And the human costs of pursuing cancer to the last is a national best seller and has been translated into nine languages.

Jeff Galvin is the CEO and Founder of American Gene Technologies. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT™ after meeting Roscoe Brady at NIH.

A nationally recognized expert in the treatment and research of lung cancer, Dr. Edelman developed one of the most commonly used regimens for treating advanced lung cancer and has focused on the development of new agents and biomarkers to personalize lung cancer therapy. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of lung cancer patients.

Dr. Edelman serves on the Lung Cancer Committee of the Alliance, the Board of Directors of the Alliance for Clinical Trials in Oncology, and the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. In addition, he is the Medical Oncology Co-chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group (RTOG) and is an active member and past chair of the Career Development and Ethics Committees of the International Association for the Study of Lung Cancer (IASLC).

Dr. Edelman has published more than 325 scientific articles, abstracts, and book chapters. In addition, he has served on the editorial boards or as a reviewer of numerous academic journals, including the New England Journal of Medicine and the Journal of Clinical Oncology, and currently serves as Associate Editor of the journal Lung Cancer.

Dr. Lin is a Professor of Radiation Oncology and a Physician-Scientist at The University of Texas MD Anderson Cancer Center. His practice focuses on thoracic malignancies. He leads clinical trials testing advanced radiation technologies or combining novel agents to enhance the current standard of care. His laboratory is also developing approaches that will enhance traditional cancer therapies. They are using drug screen approaches to identify drugs that could enhance both the cytotoxic effects but also immune stimulatory effects of radiation therapy.

Dr. Lin is also interested in approaches to identify drivers of treatment resistance and innovative strategies to counterbalance the resistance mechanisms. He is applying candidate gene knockdown or knockout screens to identify immunomodulators or radiation sensitivity modulators. The focus is on clinical translation, taking potential drug candidates and testing them in preclinical studies to validate the utility of combining radiation sensitizers or immunomodulators with standard of care chemoradiotherapy or radiotherapy alone approaches for the management of lung and esophageal cancer. Promising agents are brought to the clinic as investigator-initiated trials.